How do you define PIK3CA/AKT/PTEN alteration for capivasertib use?

For CAPItello-291, tumors had to have activating mutations in PIK3CA or AKT or inactivating alterations in PTEN genes – i.e., genes that were altered/not normal. Gene amplification refers to an increase in the number of copies of the same, normal gene, not an increased rate of transcription. So, PIK...

Currently, I am only considering activating mutations in PIK3CA/AKT as well as PTEN alterations for capivasertib use. These are the types of changes that were considered “eligible” in CAPItello-291 for the “pathway altered” analysis. That being said, there was a signal of benefit in the non-pathway ...